An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.


Updates from The Motley Fool

Latest updates on EXACT Sciences from Fool.com.  The Fool has written over 100 articles on EXACT Sciences.
Is Exact Sciences Stock a Buy?

Exact Sciences (NASDAQ: EXAS), maker of the noninvasive Cologuard colon cancer detection test, i...



Stock Performance

View Interactive EXAS Charts
Sponsored by

Key Data Points

Primary metrics and data points about EXACT Sciences.
Current Price: $14.54
Prev Close: $14.31
Open: $14.33
Bid: $13.00
Ask: $14.85
Day's Range: $14.06 - $14.60
52wk Range: $4.67 - $22.80
Volume: 1,340,936
Avg Vol 2,896,779
Market Cap: $1B
P/E (ttm): -8.37
EPS (ttm): ($1.71)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about EXACT Sciences.
CAPS Rating 2 out of 5
 
223 Outperform
37 Underperform
CAPS All Stars
 
38 Outperform
14 Underperform

How do you think EXACT Sciences will perform against the market?



You pick for EXACT Sciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Kevin T. Conroy, CEO

79% Approve

Based on 19 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for EXACT Sciences.

An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers